☆ 4.5 Review

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction Rationale and Design of the PARAGON-HF Trial

JACC-HEART FAILURE (2017)

Get Full Text
Add to Collection

Journal

JACC-HEART FAILURE
Volume 5, Issue 7, Pages 471-482

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.jchf.2017.04.013

Keywords

-

Categories

Cardiac & Cardiovascular Systems

Funding

  1. Novartis
  2. Bayer
  3. Takeda
  4. Merck
  5. AstraZeneca
  6. Janssen Research & Development, LLC
  7. Menarini
  8. Boehringer Ingelheim
  9. Abbott Diagnostics
  10. Boston Scientific
  11. Thermofisher
  12. Medtronic
  13. Vifor Pharma
  14. National Medical Research Council Singapore
  15. Sanofi
  16. DalCor
  17. Genzyme
  18. Gilead
  19. GlaxoSmithKline
  20. Janssen
  21. Lilly
  22. Medicines Company
  23. Novo Nordisk
  24. Relypsa
  25. Teva
  26. Thrasos

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.